Latest Maraviroc Stories

redOrbit Staff & Wire Reports - Your Universe Online Potentially deadly staph infections could be treated with a drug currently used by those who have been infected by HIV, according to researchers from the New York University (NYU) School of Medicine. In the study, senior author and NYU assistant professor of microbiology Dr. Victor J. Torres and colleagues discovered that maraviroc, an antiretroviral drug used to treat those who have contracted the AIDS-causing lentivirus, could...

MADISON, N.J., Oct. 2, 2012 /PRNewswire/ -- A laboratory-developed blood test that uses deep-sequencing technology performed comparably to the industry's standard phenotypic test in helping to predict potential clinical response to HIV-1 antiretroviral CCR5-antagonist therapy, according to a new study from researchers at Quest Diagnostics (NYSE: DGX) and Pfizer. The findings underscore the potential of advanced sequencing technologies to aid in the cost-effective management of...

Safety, tolerability study to enroll MSM in the United States and Puerto Rico Scientists are launching the first clinical trial to test whether drug regimens containing maraviroc, a medication currently approved to treat HIV infection, are also safe and tolerable when taken once daily by HIV-uninfected individuals at increased risk for acquiring HIV infection. The eventual goal is to see if the drug regimens can reduce the risk of infection. The trial involves a strategy known as...

RESEARCH TRIANGLE PARK, N.C., SAN DIEGO and TARRYTOWN, N.Y., Feb. 7, 2012 /PRNewswire/ -- Siemens Healthcare Diagnostics announces two new companion diagnostics partnerships with pharmaceutical companies ViiV Healthcare and Tocagen -- marking a major step for Siemens (NYSE: SI) into this important and fast-growing segment of the in vitro diagnostics (IVD) market. Both partnerships intend to leverage the clinical trial and commercialization options within Siemens' CLIA laboratory, as...

New approach redirects lymphocytes from harming vital organs, without dangers of immunosuppression An HIV drug that redirects immune cell traffic appears to significantly reduce the dangerous complication graft-versus-host disease (GvHD) in blood cancer patients following allogeneic stem cell transplantation (ASCT), according to new research from the Perelman School of Medicine at the University of Pennsylvania that will be presented today at the 53rd American Society of Hematology Annual...

LONDON, Oct. 11, 2011 /PRNewswire/ -- ViiV Healthcare announces the start of the Phase III MODERN Study [Maraviroc Once daily with Darunavir Enhanced by Ritonavir in a Novel regimen], also known as A4001095, comparing its CCR5-inhibitor, Celsentri/Selzentry® (maraviroc), to emtricitabine/tenofovir (Truvada®), both in combination with darunavir/ritonavir. The 96-week trial will evaluate a two-drug versus three-drug once-daily regimen for the treatment of antiretroviral-naive patients...

SAN FRANCISCO, Feb. 22 /PRNewswire/ -- At the 17th Conference on Retroviruses and Opportunistic Infections (CROI), ViiV Healthcare presented new data across its broad range of investigational and current medicines for the treatment of HIV/AIDS. Highlighted data at the conference included an oral presentation on the investigational integrase inhibitor, S/GSK1349572, as well as data presentations on SELZENTRY® (maraviroc) and EPZICOM® (abacavir/lamivudine). "ViiV Healthcare is...

On Tuesday, the Food and Drug Administration (FDA) announced that an HIV drug made by Pfizer appears to be safe for expanded use in patients who have not began taking other drugs to fight the terrible virus.The drug Selzentry had already been approved by the FDA as a secondary option for HIV patients who are not getting better with other antiviral drugs, but the company is now seeking the FDA's approval for the drug to be the first-choice of treatment. Tuesday's online posting of briefing...

Faster reporting aids physicians in identifying HIV mutations that can inhibit effectiveness of newest class of antiretroviral therapy MADISON, N.J., June 12 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, today announced the availability of a new laboratory developed test designed to help physicians determine whether a patient with a history of HIV drug resistance will respond to the latest...

By 2018, Gilead's Quad Will Become the Highest-Selling Antiretroviral in the World's Major Markets, According to a New Report from Decision Resources WALTHAM, Mass., May 19 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that sales of antiretroviral agents will drive substantial six percent annual growth in the HIV drug market through 2013 but significant generic erosion of key therapies thereafter...